Hidden Blood Protein May Track Insulin Resistance in Polycystic Ovary Syndrome

A little-known signaling protein that normally guides developing nerve fibers to their destinations is emerging as an unexpected player in one of the most common hormonal disorders affecting women. In a new study published in BMC Endocrine Disorders, researchers in Chongqing, China, report that circulating levels of Netrin-4, a secreted protein long studied in the context of nervous system development and blood vessel formation, are significantly elevated in women with polycystic ovary syndrome, or PCOS, and that these levels track closely with the insulin resistance and metabolic dysfunction that lie at the heart of the condition. The findings, drawn from a cross-sectional analysis combined with a series of intervention studies, suggest that Netrin-4 could serve as both a biomarker of metabolic disturbance in PCOS and a potential target for future therapies.

PCOS affects an estimated one in ten women of reproductive age and is characterized by irregular ovulation, elevated androgen hormones, and polycystic ovarian morphology. Yet the clinical presentation only scratches the surface of the disorder’s systemic reach. A large proportion of women with PCOS also exhibit insulin resistance, a state in which the body’s tissues respond poorly to the hormone insulin, forcing the pancreas to compensate with ever-higher insulin output. This metabolic derangement drives weight gain, worsens hyperandrogenism, and elevates long-term risks of type 2 diabetes and cardiovascular disease. Understanding the molecular signals that connect insulin resistance to reproductive dysfunction has therefore become a central goal of endocrinology research, and the new study adds a surprising candidate to that list.

Netrin-4 belongs to a family of laminin-related secreted proteins named after the Sanskrit word for “one who guides,” a reference to their original discovery as axon guidance cues that steer growing neurons in the embryonic nervous system. Subsequent work revealed that netrins have far broader roles, participating in angiogenesis, tissue remodeling, and inflammatory signaling. Previous studies had already hinted at a connection between Netrin-4 and obesity, but its relationship to other metabolic disorders remained unexplored. The research team, led by Xueting Cui, Mengliu Yang, Chao Fang, and Shiyao Xue of the Second Affiliated Hospital of Chongqing Medical University, set out to determine whether the protein’s circulating levels are altered in PCOS and whether those changes relate to insulin resistance specifically.

The study’s design was unusually comprehensive for a single investigation. The researchers first conducted a cross-sectional analysis comparing circulating Netrin-4 concentrations, measured with enzyme-linked immunosorbent assays, between women with PCOS and healthy controls. To assess insulin sensitivity with precision, all subjects underwent hyperinsulinemic-euglycemic clamp studies, the gold-standard technique in which insulin is infused at a fixed rate while glucose is adjusted to maintain stable blood sugar, allowing the amount of glucose required to hold levels steady to serve as a direct readout of whole-body insulin sensitivity. Participants also completed oral glucose tolerance tests, providing detailed measurements of glucose and insulin responses over time, alongside an extensive panel of metabolic and hormonal indices ranging from lipid fractions and free fatty acids to testosterone, sex hormone-binding globulin, and the free androgen index.

The results were striking. Circulating Netrin-4 levels were elevated both in women with PCOS and in subjects with insulin resistance, and the protein’s concentrations correlated significantly with a broad array of metabolic and androgen indices. In other words, the more Netrin-4 in a woman’s bloodstream, the more likely she was to show the metabolic fingerprints of PCOS, including disturbed glucose handling and altered androgen profiles. To probe what Netrin-4 might actually be doing at the cellular level, the team turned to bioinformatics, downloading transcriptome sequencing data from abdominal subcutaneous adipose stem cells derived from women with PCOS and performing differential gene expression analysis. This computational analysis revealed that the genes and signaling pathways associated with Netrin-4 were predominantly linked to fatty acid metabolism, pointing to adipose tissue as a plausible source and functional arena for the protein’s metabolic actions.

Correlation alone, however, cannot establish whether Netrin-4 merely accompanies metabolic dysfunction or actively participates in it. To address this question, the investigators enrolled 137 women with PCOS in a 24-week anti-insulin resistance treatment program, dividing participants among three therapeutic groups. The interventions included a glucagon-like peptide-1 receptor agonist, or GLP-1RA, a class of drugs famous for enhancing insulin secretion and producing substantial weight loss, and rosiglitazone, a thiazolidinedione that directly sensitizes tissues to insulin by activating the nuclear receptor PPAR-gamma. The trial was registered with the Chinese Clinical Trial Registry under identifier ChiCTR-OOC-14005314 and received ethics approval from Chongqing Medical University in compliance with the Declaration of Helsinki, with all participants providing written informed consent.

The intervention results delivered the study’s most intriguing twist. Among the three treatment groups, only the GLP-1 receptor agonist reduced circulating Netrin-4 levels, and, crucially, this effect appeared to be independent of the drug’s insulin-sensitizing action. Rosiglitazone, despite its direct effects on insulin sensitivity, did not lower Netrin-4 concentrations. This dissociation suggests that Netrin-4 is not simply a passive readout of insulin resistance that falls whenever insulin sensitivity improves. Instead, the protein may respond to specific metabolic or inflammatory pathways engaged by GLP-1 receptor agonists, pathways that could include improvements in fatty acid metabolism, adipose tissue function, or low-grade inflammation. The finding raises the possibility that Netrin-4 occupies a distinct node in the metabolic network, one that current insulin-sensitizing therapies do not uniformly reach.

The authors conclude that their results reinforce the hypothesis that Netrin-4 may function as a biomarker and potential pharmacological target in the management and understanding of insulin resistance and PCOS. If the findings are replicated in larger and more diverse cohorts, measuring Netrin-4 could eventually help clinicians identify which patients with PCOS carry the greatest metabolic burden, or serve as an early indicator of whether a given therapy is addressing the disorder’s metabolic core rather than merely its symptoms. The GLP-1RA result is particularly timely given the explosive clinical interest in this drug class, and it hints that some of the broader metabolic benefits of these agents might be mediated, at least in part, through netrin-related pathways in adipose tissue.

Significant caveats remain, as the researchers themselves acknowledge. The cross-sectional design cannot determine whether elevated Netrin-4 is a cause or a consequence of insulin resistance, and the intervention studies, while suggestive, were not designed to isolate the specific molecular mechanisms by which GLP-1 receptor agonism suppresses the protein. The bioinformatics analysis, though it implicates fatty acid metabolism, relies on transcriptomic correlations rather than direct functional experiments. Future work will need to test whether Netrin-4 directly modulates insulin signaling or lipid handling in adipocytes and other metabolically active tissues, and whether manipulating the protein in animal models alters the course of PCOS-like phenotypes. The study was supported by funding from the New Chongqing Program for Young Innovative Talents, the Chongqing Leading Medical Talents Project, the Chongqing Science and Health Joint Medical Project, and the Science and Technology Research Program of the Chongqing Municipal Education Commission, and the authors declare no competing interests.

Nevertheless, the study exemplifies a growing trend in endocrine research: the repurposing of developmental biology molecules as metabolic regulators. Proteins once dismissed as relevant only to the embryonic nervous system are increasingly recognized as active participants in adult metabolism, and Netrin-4 now joins that expanding roster. For the millions of women living with PCOS, a condition that is often diagnosed late and managed imperfectly, the identification of a circulating marker that reflects metabolic severity offers a modest but meaningful step forward. Whether Netrin-4 ultimately proves to be a useful clinical tool or a therapeutic target, the work underscores how much of metabolic disease biology remains hidden in plain sight, waiting for investigators willing to look beyond the usual suspects. The full open-access article is available in BMC Endocrine Disorders under DOI 10.1186/s12902-026-02584-5.

Subject of Research: The association of circulating Netrin-4 with insulin resistance and metabolic dysfunction in polycystic ovary syndrome

Article Title: Elevated circulating Netrin-4 levels in women with polycystic ovary syndrome: a cross-sectional study and multiple intervention studies

Article References: Cui, X., Li, Z., Tian, M., Li, K., Liu, D., Li, L., Yang, G., Liang, Z., Yang, M., Fang, C., & Xue, S. (2026). Elevated circulating Netrin-4 levels in women with polycystic ovary syndrome: a cross-sectional study and multiple intervention studies. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02584-5

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02584-5

Keywords: Netrin-4, polycystic ovary syndrome, insulin resistance, GLP-1 receptor agonist, rosiglitazone, biomarker, fatty acid metabolism, adipose tissue, metabolic disorder, hyperinsulinemic-euglycemic clamp, endocrinology, hyperandrogenism